title: Prospective multicenter clinical trial of Chinese herbal formula JZQG (Jiangzhuoqinggan) for hypertension.
abstract: A prospective multicenter clinical trial was conducted to compare the beneficial effects of a Chinese herbal medicine formula Jiangzhuoqinggan (JZQG) and western antihypertension drug irbesartan. JZQG is mainly composed of rhubarb, coptis, cassia, and uncaria. A total of 240 patients with mild to moderate hypertension were enrolled in the trial. Patients were assigned into two groups after screening: JZQG group and the irbesartan group. After four weeks of treatment, we compared the changes in routine blood pressure, 24 h ambulatory blood pressure, and waist circumference. There was a significant reduction in systolic blood pressure and diastolic blood pressure in the JZQG group (both p < 0.01). There were no significant differences between the reduction of systolic and diastolic blood pressures in the two treatment groups. From the 24 h ambulatory blood pressure measurement, the JZQG group showed a greater reduction in both systolic and diastolic blood pressures (in both daytime and nighttime) than the irbesartan group. Furthermore, there was a significant difference in waist circumference in the JZQG group (1.51 cm reduction; P < 0.05) but not the irbesartan group (0.42 cm). Thus, the JZQG formula may have therapeutic value in patients with both hypertension and metabolic syndrome.
authors: Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053,  China.
authors: Xiao-Lin
authors: XL
authors: Tong
authors: Feng-Mei
authors: FM
authors: Lian
authors: Qiang
authors: Q
authors: Zhou
authors: Li-Peng
authors: LP
authors: Xu
authors: Hang-Yu
authors: HY
authors: Ji
authors: Gui-Cheng
authors: GC
authors: Xu
authors: Yuan-Hui
authors: YH
authors: Hu
authors: Lin-Hua
authors: LH
authors: Zhao
authors: Le
authors: L
authors: Xia
authors: Jia
authors: J
authors: Wang
authors: Xin-Yan
authors: XY
authors: Chen
authors: Man-Hon
authors: MH
authors: Chan
authors: Lan-Lan
authors: LL
authors: Zhang
authors: Wen
authors: W
authors: Gao
authors: Zhong
authors: Z
authors: Zhen
authors: Shui-Ping
authors: SP
authors: Zhou
authors: Bai
authors: B
authors: Chang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000494:pharmacology / Q000627:therapeutic use; D004365:Drugs, Chinese Herbal / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D000077405:Irbesartan; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy; D008875:Middle Aged; D011446:Prospective Studies; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use; D055105:Waist Circumference / Q000187:drug effects; D055815:Young Adult
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D004365:Drugs, Chinese Herbal; D013777:Tetrazoles; D000077405:Irbesartan